Lilly completes Phase 3 ATTAIN-J trial of oral orforglipron in Japanese obesity patients
Results posted for a completed Phase 3 study testing once-daily oral orforglipron against placebo in Japanese adults with obesity.
This week's update covers a single Phase 3 trial from Eli Lilly and Company.
- Eli Lilly's Phase 3 trial "ATTAIN-J" (NCT05931380) tested once-daily oral orforglipron (LY3502970) against placebo in Japanese adults with obesity disease. The study aimed to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.1 The trial is listed as completed, with enrollment of 238 participants (actual)1, and results were first posted on 2026-07-20. The primary outcome was Percent Change From Baseline in Body Weight at Week 721.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.